FDA authorizes bivalent COVID boosters for younger children
The Food and Drug Administration (FDA) on Wednesday announced it has amended its emergency authorization of the bivalent COVID-19 boosters to include children between the ages of 5 and 11. The FDAs decision grants Modernas request for authorization to administer its bivalent booster to children as young as 6 and grants Pfizers request to
Wednesday, October 12, 2022 at 2:44 pm